JPRN-UMIN000014740尚未招募2 期
Phase 2 study of efficacy and safety of concurrent WBRT with erlotinib and followed by erlotinib plus bevacizumab in patients with newly diagnostic brain metastatisis stage IV non-sq NSCLC - Phase 2 study of concurrent WBRT with erlotinib and followed by erlotinib plus bevacizumab in patients with brain metastatisis stage IV non-sq NSCLC
Shinshu University Hospital, Comprehensive Cancer Center0 个研究点目标入组 24 人开始时间: 2014年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Current history of hemosputum within one month 2) Past given the radiation therapy for chest 3) Symptomatic meningeal dissemination 4) Patients who have previously treated with EGFR TKI within 6 months 5) Obvious interstitial pneumonia , fibroid lung confirmed by chest X-ray 6) Patients unable to be treated with oral medication 7) Therapeutic anticoagulation; regular use of aspirin (>325 mg/day) 8) Scleroderma, systemic lupus erythematosus, dermatomyositis, or polymyositis 9) Infectious disease that required systemic therapy 10) Fever over 38 11) Uncontrolled pleural effusion, ascites, or pericardial effusion 12) Active synchronous malignant neoplasm 13) History of drug allergy that may influenced with this treatment 14) Severe GI disease 15) Suspected of other severe clinical conditions or abnormal laboratory values 16) Uncontrolled psychotic disease 17) Pregnant, Lactating or possibility of pregnancy 18) Patients who were judged inappropriate to entry this study by physician
研究者
相似试验
进行中（未招募）
1 期
A phase II study evaluating the use of concurrent cetuximab, irinotecan, oxaliplatin and UFT in the first line treatment of patients with metastatic colorectal cancer - e-SCOUTAdvanced, inoperable or metastatic colorectal cancer.EUCTR2007-002053-24-GBThe Christie NHS Foundation Trust
进行中（未招募）
1 期
Study the effects of azacitidine and lenalidomide combination therapy in patients with acute myeloid leukemiaMedDRA version: 21.0Level: LLTClassification code 10024289Term: Leukaemia acuteSystem Organ Class: 100000004864ACUTE MYELOID LEUKEMIAEUCTR2015-001767-40-ITAZIENDA OSPEDALIERA OSPEDALI RIUNITI MARCHE NORD66
进行中（未招募）
不适用
A two-stage multicenter phase II trial of concurrent panitumumab immunotherapy, cisplatin chemotherapy and pelvic radiotherapy for primary cancer of the uterine cervix stage Ib-IIIb - AGO 20primary cancer of the uterine cervix stage Ib-IIIbEUCTR2009-012453-38-ATStudienzentrale AGO Austria
进行中（未招募）
1 期
A two-stage multicenter phase II trial of concurrent induction chemoimmunotherapy with epirubicine, oxaliplatin, capecitabine and panitumumab in KRAS wild-type, resectable type II gastric adenocarcinoma - Gastric 4MedDRA version: 12.1Level: LLTClassification code 10017764Term: Gastric cancer stage IIMedDRA version: 12.1Level: LLTClassification code 10017765Term: Gastric cancer stage IIIMedDRA version: 12.1Level: LLTClassification code 10017768Term: Gastric cancer stage IV without metastasesGastric cancerEUCTR2009-011337-27-ATAGMT
已完成
不适用
Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.s diseaseParkinson's diseaseJPRN-UMIN000030930StaGen Co. Ltd.30